QUEST DIAGNOSTICS INC
Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.
CAPITALIZATION 12/31/25
| ($ millions) | Amount | % |
|---|---|---|
| Total debt | 5,671 | 44.2 |
| Stockholders' equity | 7,170 | 55.8 |
| Total capitalization | 12,841 | 100.0 |
110,373,360 shares outstanding at 15 July 2026 (cover page of the 10-Q filed 23 July 2026).
LONG-TERM DEBT 12/31/25
| ($ millions) | Amount |
|---|---|
| Long-term debt, incl. current maturities | 5,671 |
| Long-term debt, noncurrent | 5,167 |
| Current maturities | 504 |
CAPITAL STOCK 12/31/25
| Common shares authorized | 600,000,000 |
| Common shares issued | 162,000,000 |
| Treasury shares | 52,000,000 |
| Par or stated value per share ($) | 0.01 |
| Outstanding at 7/15/26 | 110,373,360 |
DIVIDENDS DECLARED/PAID
| Fiscal year | Per share $ | Payout % |
|---|---|---|
| 2025 | – | – |
| 2024 | – | – |
| 2023 | – | – |
| 2022 | – | – |
| 2021 | – | – |
HISTORY AND BUSINESS
HISTORY: Incorporated in Delaware. Formerly known as CORNING CLINICAL LABORATORIES INC (to 19 March 1997).
BUSINESS: Classified by the SEC under Standard Industrial Classification 8071, Services-Medical Laboratories. Large accelerated filer. Principal executive office: 500 Plaza Drive, Secaucus, NJ 07094. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.
CONSOLIDATED INCOME ACCOUNT, YEARS ENDED
| ($ millions) | 12/31/25 | 12/31/24 | 12/31/23 |
|---|---|---|---|
| Revenues | 11,035 | 9,872 | 9,252 |
| Cost of revenues | 7,370 | 6,628 | 6,199 |
| Selling, general and administrative | 1,967 | 1,770 | 1,642 |
| Depreciation and amortization | 570 | 493 | 439 |
| Operating income | 1,556 | 1,346 | 1,262 |
| Interest expense | – | – | 163 |
| Income before income taxes | 1,318 | 1,175 | 1,130 |
| Income taxes | 314 | 273 | 248 |
| Net income | 992 | 871 | 854 |
| Earned per share, diluted ($) | 8.75 | 7.69 | 7.49 |
| Dividends per share ($) | – | – | – |
CONSOLIDATED BALANCE SHEET
| ($ millions) | 12/31/25 | 12/31/24 |
|---|---|---|
| Cash and equivalents | 420 | 549 |
| Receivables, net | 1,408 | 1,304 |
| Inventories | 189 | 188 |
| Total current assets | 2,378 | 2,392 |
| Property, plant and equipment, net | 2,203 | 2,113 |
| Goodwill | 8,945 | 8,856 |
| Total assets | 16,225 | 16,153 |
| Total current liabilities | 2,278 | 2,169 |
| Long-term debt | 5,167 | 5,615 |
| Stockholders' equity | 7,170 | 6,778 |
| Total liabilities and equity | 16,225 | 16,153 |
TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)
| Fiscal year ended | Revenues | Oper. income | Net income | Net margin % | EPS diluted $ | Div. per share $ | Oper. cash flow | Capital expend. | Free cash flow | Total assets | Total liabilities | Total debt | Stockholders' equity | ROE % | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/31/25 | 11,035 | 1,556 | 992 | 9.0 | 8.75 | – | 1,886 | 527 | 1,359 | 16,225 | 9,019d | 5,671 | 7,170 | 13.8 | 0.79 |
| 12/31/24 | 9,872 | 1,346 | 871 | 8.8 | 7.69 | – | 1,334 | 425 | 909 | 16,153 | 9,340d | 6,217 | 6,778 | 12.9 | 0.92 |
| 12/31/23 | 9,252 | 1,262 | 854 | 9.2 | 7.49 | – | 1,272 | 408 | 864 | 14,022 | 7,680d | 4,713 | 6,307 | 13.5 | 0.75 |
| 12/31/22 | 9,883 | 1,428 | 946 | 9.6 | 7.97 | – | 1,718 | 404 | 1,314 | 12,837 | 6,907d | 3,980 | 5,893 | 16.1 | 0.68 |
| 12/31/21 | 10,788 | 2,381 | 1,995 | 18.5 | 15.55 | – | 2,233 | 403 | 1,830 | 13,611 | 7,128d | 4,012 | 6,444 | 31.0 | 0.62 |
| 12/31/20 | 9,437 | 1,971 | 1,431 | 15.2 | 10.47 | – | 2,005 | 418 | 1,587 | 14,026 | 7,217d | 4,015 | 6,759 | 21.2 | 0.59 |
| 12/31/19 | 7,726 | 1,231 | 858 | 11.1 | 6.28 | – | 1,243 | 400 | 843 | 12,843 | 7,156d | 4,770 | 5,641 | 15.2 | 0.85 |
| 12/31/18 | 7,531 | 1,101 | 736 | 9.8 | 5.29 | – | 1,200 | 383 | 817 | 11,003 | 5,736d | 3,893 | 5,216 | 14.1 | 0.75 |
| 12/31/17 | 7,402 | 1,165 | 772 | 10.4 | 5.50 | 1.80 | 1,175 | 252 | 923 | 10,503 | 5,548d | 3,784 | 4,921 | 15.7 | 0.77 |
| 12/31/16 | 7,214 | 1,277 | 645 | 8.9 | 4.51 | 1.65 | 1,116 | 293 | 823 | 10,100 | 5,440d | 3,734 | 4,628 | 13.9 | 0.81 |
Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.
REGISTRANT:
QUEST DIAGNOSTICS INC
CIK 1022079 · EIN 16-1387862
PRINCIPAL OFFICE:
500 Plaza Drive, Secaucus, NJ 07094
Tel.: 9735202700
INCORPORATED:
Delaware
INDUSTRY (SEC SIC CODE):
8071 · Services-Medical Laboratories
FILER STATUS:
Large accelerated filer
LATEST ANNUAL REPORT:
10-K for period ended 12/31/25, filed 26 February 2026
FORMER NAMES:
CORNING CLINICAL LABORATORIES INC
Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/26/26) · 10-K FY2024 (filed 2/20/25) · 10-K FY2023 (filed 2/22/24) · 10-K FY2022 (filed 2/21/23) · 10-K FY2021 (filed 2/28/22) · 10-K FY2020 (filed 2/22/21) · 10-K FY2019 (filed 2/20/20) · 10-K FY2018 (filed 2/21/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.
Data from SEC filings. © 2026 Pathos Investments · pathosinvestments.com · For educational purposes only. Not investment advice.